VIDA Diagnostics Inc. news
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. This clearance further validates the quality and clinical efficacy of the company’s artificial intelligence (
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has onboarded more than 1,000 sites globally in its VIDA network of imaging sites. This network is connected through the VIDA Intelligence Portal, a cloud native AI-enabled platform that drives efficiencies in clinical trial imaging operations by optimizing site recruitment and onboarding, staff training, image data collection, data quality, data curation, and more.<
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage VIDA’s unique AI-enabled biomarker generation service
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has announced it has secured financing as it scales up to support strong demand for its VIDA Intelligence Portal, an AI-powered solution that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality. Since launching this latest addition to VIDA`s platform five months ago, demand has driven VID
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has received market authorization in Japan for its VIDA Insights® software, paving the way for lung care teams to begin using the solution at the point of care. Clairvo Technologies, Inc., a wholly owned subsidiary of Marubeni Corporation, secured the certification from Japan’s Pharmaceuticals and Medical Devices Agency.
“I am pleased that VID
VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. L
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, today announced a new strategic partnership with Peoria, Illinois-OSF HealthCare that will make VIDA Insights available to care teams across the organization. VIDA and its comprehensive, lung intelligence solutions continue to gain traction among integrated delivery network (IDN) health care providers ac
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has signed an agreement with UnityPoint Health to implement VIDA’s AI-powered lung intelligence and imaging solutions across the UnityPoint Health system.
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it is has appointed Karen Drexler to its board of directors, further expanding the company’s leadership strength in digital health technology.
Drexler’s appointment comes at a critical time in healthcare, as the world continues to address the potential long-term lung health implications of the COVID-19 pandemic.
VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, announced today that Todd Johnson has joined the company as chief technology officer.
Johnson, a leader in enterprise imaging and advanced clinical applications, will apply his expertise to extend the breadth and depth of VIDA’s LungPrint solutions, ensuring the company’s AI (artificial intelligence) insights are accessible to a broader base of cl